ArticlePharmacoEconomics - open2022

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.

Holly Cranmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.